| Type de cancer | Acronyme | Numéro NCT | Titre | Phase | Stade | Biomarqueurs | Ligne de traitement | Site | Personne contact |
|---|---|---|---|---|---|---|---|---|---|
| Endometrial cancer | 2870-005 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005) | PHASE3 | RECURRENT, REFRACTORY | N/A | GREATER_THAN_SECOND_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen phuong-nam.nguyen@mail.mcgill.ca 514 934-1934 #23985 | |
| Endometrial cancer | 2870-005 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005) | PHASE3 | RECURRENT, REFRACTORY | N/A | GREATER_THAN_SECOND_LINE | CIUSSS du Saguenay-Lac-Saint-Jean | Sabrina Côté, Katryne Lepage | |
| Endometrial cancer | 2870-005 | NCT06132958 | MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005) | PHASE3 | RECURRENT, REFRACTORY | N/A | GREATER_THAN_SECOND_LINE | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Ovarian Cancer | A10-M84-07A | NCT02296307 | DOvEE - Diagnosing Ovarian & Endometrial Cancer Early | NA | PREVENTION | N/A | NA | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Ovarian Cancer | BTDOCID-1483282069-8590 | Creation of a virtual human twin as a tool for cancer detection assistance,Création d'un jumeau humain virtuel comme outil d'aide à la détection du cancer | NA | ANY_STAGE | N/A | NA | BioTwin | ||
| Ovarian Cancer | C042800 | NCT01862081 | A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer | PHASE1 | ADVANCED, METASTATIC | HER2-, HR+, TRIPLE NEGATIVE | NA | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Alessandra Vasconcelos |
| Cervix Cancer | CA052-002 | NCT04895709 | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors,Étude visant à évaluer le BMS-986340 administré en monothérapie et en association avec le nivolumab chez des participants atteints de tumeurs solides de stade avancé | PHASE1, PHASE2 | ADVANCED | N/A | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | Adeline Hamon |
| Endometrial cancer | CO2re Intima | NA | ANY_STAGE | N/A | NA | CHU de Québec - Université Laval | Josée Allard | ||
| Endometrial cancer | CO44195 | NCT05634499 | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | PHASE2 | NA | N/A | 1re ligne | McGill University Health Centre | |
| Endometrial cancer | CO44195 | NCT05634499 | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | PHASE2 | NA | N/A | 1re ligne | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Alessandra Vasconcelos |
| Cervix Cancer | CONTESSA/NeoConF | NCT04016389 | FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | NA | EARLY | N/A | ADJUVANT | CHU de Québec - Université Laval | Maryse Gingras |
| Cervix Cancer | CONTESSA/NeoConF | NCT04016389 | FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery | NA | EARLY | N/A | ADJUVANT | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Ovarian Cancer | D9720C00001 - PETRA | NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | PHASE1, PHASE2 | ADVANCED, METASTATIC | BRCA1/2, PALB2/HDR, RAD51C, RAD51D | GREATER_THAN_SECOND_LINE, SECOND_LINE | Centre hospitalier de l'Université de Montréal | Adeline Hamon |
| Ovarian Cancer | D9720C00001 - PETRA | NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | PHASE1, PHASE2 | ADVANCED, METASTATIC | N/A | GREATER_THAN_SECOND_LINE, SECOND_LINE | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Alessandra Vasconcelos, Annabelle Dormevil |
| Ovarian Cancer | Exactis-03 | NCT05358639 | Combination of Olaparib and Navitoclax in Women With HGSC and TNBC | PHASE1 | RECURRENT, ADVANCED, METASTATIC | BRCA1/2, PALB2 | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | Lynda Abdelguerfi |
| Ovarian Cancer | GARNET | NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | PHASE1 | ADVANCED | PD-1, PD-L1 | GREATER_THAN_FIRST_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Ovarian Cancer | GARNET | NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | PHASE1 | ADVANCED | N/A | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Cervix Cancer | GO43860 | NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | PHASE1 | ADVANCED, METASTATIC, RECURRENT | N/A | SECOND_LINE | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Ding Yuan Guo |
| Cervix Cancer | GOG-3043 | NCT04831580 | A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | NA | EARLY | N/A | 1re ligne | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Cervix Cancer | GOG-3043 | NCT04831580 | A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | NA | EARLY | N/A | 1re ligne | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Ovarian Cancer, Peritoneal Cancer | IMGN853-0421 | NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA) | PHASE3 | RECURRENT, ADVANCED | FRA+, BRCA1/2 | GREATER_THAN_SECOND_LINE | CIUSSS de l'Est-de-l'Île-de-Montréal | Samara Bloom |
| Ovarian Cancer, Peritoneal Cancer | IMGN853-0421 | NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA) | PHASE3 | RECURRENT, ADVANCED | FRA+, BRCA1/2 | GREATER_THAN_SECOND_LINE | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Ovarian Cancer, Peritoneal Cancer | IMGN853-0421 | NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA) | PHASE3 | RECURRENT, ADVANCED | FRA+, BRCA1/2 | GREATER_THAN_SECOND_LINE | CIUSSS de l'Estrie-CHUS | Annie Bourbonnais |
| Ovarian Cancer, Peritoneal Cancer | IMGN853-0421 | NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA) | PHASE3 | RECURRENT, ADVANCED | FRA+, BRCA1/2 | GREATER_THAN_SECOND_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Cervix Cancer, Endometrial cancer | KL264-01 | NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies | PHASE1, PHASE2 | METASTATIC, REFRACTORY | HR+, HER2+, TRIPLE NEGATIVE | GREATER_THAN_FIRST_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Endometrial cancer | KRT-232-118 | NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | PHASE2, PHASE3 | ADVANCED, RECURRENT | P53 | SECOND_LINE | CHU de Québec - Université Laval | Maryse Gingras |
| Endometrial cancer | KRT-232-118 | NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | PHASE2, PHASE3 | ADVANCED, RECURRENT | P53 | SECOND_LINE | Centre hospitalier de l'Université de Montréal | |
| Cervix Cancer, Endometrial cancer, Vulvar Cancer | MK-3475-158 | NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | PHASE2 | ADVANCED | PD-1, PD-L1 | GREATER_THAN_FIRST_LINE | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Ivgenya Kosenko |
| Endometrial cancer | MK-4280A-010 | NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | PHASE2 | ADVANCED, METASTATIC, RECURRENT | PD-1, PD-L1, PMMR | GREATER_THAN_FIRST_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Endometrial cancer | MK-4280A-010 | NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | PHASE2 | ADVANCED, METASTATIC, RECURRENT | PD-1, PD-L1, PMMR | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Endometrial cancer | MK-4280A-010 | NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | PHASE2 | ADVANCED, METASTATIC, RECURRENT | PD-1, PD-L1, PMMR | GREATER_THAN_FIRST_LINE | CHU de Québec - Université Laval | Maryse Gingras |
| Ovarian Cancer, Peritoneal Cancer | NRG-GY019 | NCT04095364 | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PHASE3 | ADVANCED | P53, TP53 | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | 06CHUMDREC Recherche Clinique Gynécologie-oncologie |
| Cervix Cancer, Ovarian Cancer | OCEL-01 | NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,Étude visant à évaluer l’innocuité et la pharmacocinétique de l’OC-001 chez les patients atteints de cancers localement avancés ou métastatiques | PHASE1, PHASE2 | ADVANCED, METASTATIC | N/A | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | Chantal Légaré, Marie-Ève Rego |
| Cervix Cancer, Ovarian Cancer | OCEL-01 | NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,Étude visant à évaluer l’innocuité et la pharmacocinétique de l’OC-001 chez les patients atteints de cancers localement avancés ou métastatiques | PHASE1, PHASE2 | ADVANCED, METASTATIC | TRIPLE NEGATIVE | GREATER_THAN_FIRST_LINE | CIUSSS du Centre-Ouest-de-l’Île-de-Montréal | Ivgenya Kosenko |
| Endometrial cancer | PROMISE | NA | ANY_STAGE | N/A | NA | Centre hospitalier de l'Université de Montréal | France Gauthier | ||
| Cervix Cancer | RTOG 0724 | NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | PHASE3 | EARLY | N/A | ADJUVANT | McGill University Health Centre | Ginette Ricard |
| Cervix Cancer | SENTICOL III - CX6 | NCT03386734 | International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | NA | EARLY | N/A | 1re ligne | CIUSSS de l'Est-de-l'Île-de-Montréal | Audrey Lamoureux, Samara Bloom |
| Cervix Cancer | SENTICOL III - CX6 | NCT03386734 | International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer | NA | EARLY | N/A | 1re ligne | CHU de Québec - Université Laval | Maryse Gingras |
| Endometrial cancer, Ovarian Cancer | SGNDV-005 | NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | PHASE2 | ADVANCED, RECURRENT | HER2+ | GREATER_THAN_SECOND_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Endometrial cancer, Ovarian Cancer | SGNDV-005 | NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | PHASE2 | ADVANCED, RECURRENT | HER2+ | GREATER_THAN_SECOND_LINE | CHU de Québec - Université Laval | Maryse Gingras |
| Endometrial cancer, Ovarian Cancer | TH1902-CTR-0001 | NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | PHASE1 | ADVANCED, METASTATIC, REFRACTORY | TRIPLE NEGATIVE, HR+ | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | Adeline Hamon |
| Endometrial cancer, Ovarian Cancer | TROPION-PanTumor03 - Gastric | NCT05489211 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | PHASE2 | ADVANCED, METASTATIC | N/A | 1re ligne | McGill University Health Centre | Ryan Liu |
| Endometrial cancer, Ovarian Cancer | TROPION-PanTumor03 - Gastric | NCT05489211 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | PHASE2 | ADVANCED, METASTATIC | N/A | 1re ligne | CHU de Québec - Université Laval | Philippe Nadeau |
| Endometrial cancer, Ovarian Cancer | TROPION-PanTumor03 - Prostate Cancer | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03), | PHASE2 | ADVANCED, METASTATIC | N/A | 1re ligne | McGill University Health Centre | Rodrigo Skowronski | |
| Endometrial cancer | XPORT-EC-042 | NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | PHASE3 | RELAPSED, ADVANCED | P53 | GREATER_THAN_FIRST_LINE | McGill University Health Centre | Phuong-Nam Nathalie Nguyen |
| Endometrial cancer | XPORT-EC-042 | NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | PHASE3 | RELAPSED, ADVANCED | P53 | GREATER_THAN_FIRST_LINE | Centre hospitalier de l'Université de Montréal | Josée Tremblay |
Q-CROC | Consortium de recherche en oncologie clinique du Québec
Québec (Québec), Canada